

04th Knowledge Series for Genitourinary Cancers - Year In Review Day 1 29th April,2023		
Time	Topic	Speaker
	Registration	
08:55 am - 09:00 am	Welcome and Introduction	Dr. Puneet Ahluwalia, Delhi
	SESSION 1	
	Session Coordinator	TBC
	PROSTATE : Non Metastatic	
	Chairperson	Dr. Ghose Dr. Gaurang Shah Dr Kannan
09:00 am - 09:10 am	Outcomes of Grade Group 2 and 3 Prostate Cancer on Initial Versus Confirmatory Biopsy: Implications for Active Surveillance: (M Perrera Eur Urol Focus 2022 Dec)	Dr. Harkirat Talwar, Delhi
09:10 am -09:20 am	: PACE-A: An International Phase 3 Randomised Controlled Trial (RCT) Comparing Stereotactic Body Radiotherapy (SBRT) to Surgery for Localised Prostate Cancer (LPCa)—Primary Endpoint Analysis	Dr Swarupa Mitra, Delhi
09:20 am -09:30 am	Neoadjuvant Novel Hormonal Therapy Followed by Prostatectomy versus Up-Front Prostatectomy for High-Risk Prostate Cancer: A Comparative Analysis	Dr. Sauarbh Vashishtha, Bangalore
09:30 am - 09:40 am	Retzius Sparing Radical Prostatectomy Versus Robot- assisted Radical Prostatectomy: Which Technique Is More Beneficial for Prostate Cancer Patients (MASTER Study)? A Systematic Review and Meta- analysis	Dr. Ashish Khanna, Delhi
09:40 am - 09:50 am	Radioisotope-guided Lymphadenectomy for Pelvic Lymph Node Staging in Patients With Intermediate- and High-risk Prostate Cancer (The Prospective SENTINELLE Study)	Dr. Srivatsa Narsimhan, Bangalore
9:50 am - 10:00am	LBA9 - Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: First results of the RADICALS-HD trial (ISRCTN40814031)	Dr Manish Chandra, Mumbai
10:00 am - 10:40 am	Moderator	Dr. Sanjai Addla, Hyderabad
	Panelist	Dr. Ginil Kumar, Kochi
	Panelist	Dr Manav Suryavanshi, Delhi
	Panelist	Dr. Aditya Pradhan
	Panelist	Dr. Tarun Jindal, kolkata
	Panelist	Dr. Hemant Tangaokar, Mumbai
	Panelist	Dr Animesh Saha, kolkata

	Panelist	Dr Sharmila Agarwal		
		Dr Suparna Rao ,Mumbai		
10:40 am - 10:45 am				
	SESSION 2			
	Chairpersons:	Dr Pankaj Maheshwari, Dr Sharmila Agarwal, Dr Bhalavat		
10:45 am - 10:55 am	Pooled outcomes of performing freehand transperineal prostate biopsy with the PrecisionPoint Transperineal Access System(BJUI Compass. 2022 Jun)	Dr. Ashwin Tamhankar, Mumbai		
10:55 am -11:05 am	Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience	Dr. Himesh Gandhi, Pune		
11:05 am- 11:15 am	Superior Post-Treatment Biopsy Outcomes with High Dose SBRT Compared to High-Dose Conventionally Fractionated IMRT for Clinically Localized Prostate Cancer	Dr Pooja Nandwani Patel, Ahmedabad		
11:15am - 11:25am	FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP). (oral abstract 303)	Dr Prahlad Yathiraj, Chennai		
11:25am - 11:35 am	Sequencing of Androgen Deprivation Therapy of Short Duration with Radiotherapy for Non-Metastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials	Dr Trinanjan Basu Mumbai		
11:35 am- 11:45 am	Impact of PSMA PET/CT on Prostate Cancer Salvage Radiotherapy Management: Results from the Prospective Randomized Phase 3 Trial [PSMA SRT NCT03582774]	Dr Ritika Harjani Hinduja Mumbai		
11:45 am - 12:25 pm				
	Moderator	Dr Vedang Murthy Mumbai		
	Panelist	Dr. Makarand Kochikar,		
	Panelist	Dr. N Ragavan		
	Panelist	Dr Haresh KP,Delhi		
	Panelist	Dr Deepak Abrol,Jammu		
	Panelist	Dr Ram Alva,Bangalore		
	Panelist	Vamshi Krishna ,Hyderabad		
12:25 pm - 12:30 pm				

	SESSION 3			
	Chairperson - RO, MO, MO	Dr Haresh Kp, Vanita Norohna,		
	Prostate : Systemic Therapy (Metastatic)			
12:30pm - 12:40 pm	Feasibility and safety of radical prostatectomy for oligo- metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligo-Metastases to the bone (TRoMbone) trial	Dr. Milap Shah, Ahemdabad		
12:40pm - 12:50 pm	NRG-GU011: A Phase II Double-Blinded, Placebo-Controlled Trial of Prostate Oligometastatic Radiotherapy with or Without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN)/	Dr. Anup Toshniwal, Aurangabad		
12:50 pm -01:05 pm	TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide Versus Placebo + ENZA as First-Line Treatment in Patients with mCRPC, "Final overall survival (OS) in PROpel: Abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC)."	Dr. Vamshi Krishna, Hyderabad		
1:05pm - 1:15pm	- Pembrolizumab + olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study	Dr. Bharat Vaswani, Hyderabad		
1:15pm -1:25pm	Early results from a phase 1, multicenter trial of PSCA-specific GoCAR T cells (BPX-601) in patients with metastatic castration-resistant prostate cancer (mCRPC). (poster 140)	Dr. Nandani Menon, Mumbai		
1:25 pm -1:35 pm	177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in mCRPC Progressing After Docetaxel—Overall Survival After Median Follow-Up of 3 Years (ANZUP 1603) - TheraP	Dr. Deepak Dabkara, Indore		
1:35 pm -1:45 pm	NRG-GU011: A Phase II Double-Blinded, Placebo-Controlled Trial of Prostate Oligometastatic Radiotherapy with or Without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG PROMETHEAN)	Dr Gagan Saini, Delhi		
1:45 pm- 2:15 pm				
	Panel Discussion	Dr. Vineet Talwar, Delhi		
	Panelist	Aseem Samar		
	Panelist	Vivek Agarwalla		
	Panelist	Dr Rohit Pai, Mumbai		
	Panelist	Dr Ajay Singh, Mumbai		
	Panelist	Dr Sumit Basu, Pune		
	Panelist	Dr TB Yuvraja, Mumbai		

	Panelist	Dr Parneet Singh, chandigarh		
2:15 pm- 2:20 pm	Expert Comments	Dr Vanita		
2:20 pm - 3:05 pm	Lunch Break			
	SESSION 4			
	Renal Cell Carcinoma			
	Chairperson-Dr. NP Gupta, Dr. Hemant Pathak, Dr. Swarupa Mitra			
3:05 pm - 3:15pm	Renal cell carcinoma in renal transplant recipients : Is there a role of screening?	Dr. Mayank Agrawal, Delhi		
3:15 pm - 3:25pm	Development and Validation of a Nomogram Predicting Intraoperative Adverse Events During Robot-assisted Partial Nephrectomy:	Dr. Gopal Sharma, Delhi		
3:25 pm - 3:35pm	Identifying patients for adjuvant therapy after nephrectomy U capitano: lancet 2022	Dr. Rakesh Sharma, Hyderabad		
3:35pm - 3:45pm	Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with eckpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium	Dr. Mahendra Pal, Mumbai		
3:45pm - 3:55pm	Bone Only Oligometastatic Renal Cell Carcinoma Patients Treated with Stereotactic Body Radiotherapy: A MULTI-Institutional Study	Dr. Sayan Paul, Kolkata		
3:55 pm- 4:05 pm	Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System	Dr. Priyamvada Mhatre, Mumbai		
4:05 pm- 4:45 pm	Moderator	Dr. Ganesh Bakshi, Mumbai		
	Panelist	Dr. Kishore TA, Kochi		
	Panelist	Dr Sujoy Gupta, Kolkata		
	Panelist	Dr. Anil Mandhani, Delhi		
	Panelist	Dr. Amit Ghose, Kolkata		
	Panelist	Dr. Sanjoy Surekha, lucknow		
	Panelist	Dr. Kaustav Talapatra, Mumbai		
	Panelist	Dr. Bhavin Visariya, Mumbai		
4:45pm - 4:50 pm				
4:50 pm- 5:20pm	Tea Break			
	Session 5			
	Chairpersons:	Dr. Percy Chibber, Dr. Amit Joshi, Mumbai; Dr. Sachin Almel		

5:20 pm - 5:30pm	LBA66 - IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection + LBA4 - Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial	Dr HS. Darling, Bengaluru		
5:30 pm- 5:40 pm	Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial (oral abstract 603)	Dr. Vijay Patil, Mumbai		
5:40 pm- 5:50pm	LBA 8-Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)	Dr. Aseem Samar, Jaipur		
5:50 pm- 6:00 pm	1462P - Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a)	Dr. Vivek Agarwala, Kolkata		
6:00 pm- 6:10 pm				
6:10pm- 6:20pm				
6:20 pm- 7:00 pm				
	Moderator	Dr. Amish Vora, Delhi		
		Dr. Tejinder Singh, Mumbai		
	Panelist	Dr. Vijay Patil, Mumbai		
	Panelist	Dr. Shivam Shingla, Mumbai		
	Panelist	Dr. Pritam Kataria, Mumbai		
	Panelist	Dr. Amol Dongre, Nagpur		
	Panelist	Dr. Amol Patel, Mumbai		
	Panelist	Dr. Amandeep Arora, Mumbai		
7:00pm - 7:05pm		Dr. Amit Joshi, Mumbai		
7:05 pm- 7:20pm	Industry Symposium 1			
7:20 pm -8:05 pm	Industry Symposium 2			
8:05 pm- 8:50 pm	Industry Symposium 3			

4th Knowledge Series for Genitourinary Cancers - Year In Review Day 2 (30th, April 2023)			
Slot	Time	Topic	Speaker
		Welcome and Introduction	
		SESSION 1	
		Urothelial Cancer	
		Chairperson	Dr Ajit Sawant(UO), Dr Anil Mandhani(UO)Dr Vivek Anand
10 min	09:00 am - 9:10 am	First results from BladderPath: A randomised trial of MRI versus cystoscopic staging for newly diagnosed bladder cancer	Dr. Amandeep Arora, Mumbai
10 min	9:10 am - 09:20 am	NOVEL THERAPIES FOR HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER.	Dr. Uday Pratap, Lucknow
10 min	09:20 am - 09:30 am	COMPARISON OF ROBOT-ASSISTED AND OPEN RADICAL CYSTECTOMY IN RECOVERY OF PATIENT-REPORTED AND PERFORMANCE-RELATED MEASURES OF INDEPENDENCE SECONDARY ANALYSIS OF A RANDOMIZED CLINICAL TRIAL	Dr. Vivek Venkatramani, Mumbai
10 min	09:30 am - 09:40 am	Bladder only versus bladder plus pelvic node chemoradiation for muscle invasive bladder cancer S.A. Patel, Y.Liu	Dr Prasad Raj Dandekar, Mumbai
10 min	09:40 am - 09:50 am	Neoadjuvant Chemotherapy before Nephroureterectomy in High-Risk Upper Tract Urothelial Cancer: A Systematic Review and Meta-Analysis	Dr. Himanshu Pandey, Varanasi
10 min	09:50 am - 10:00 am	Survival outcome compare radical nephroureterectomy vs endoscopy treatment in solitary kidney patients diagnosed with tract urothelial carcinoma	Dr. Ankur Mittal, Rishikesh
10 min	10:00 am - 10:10 am	Effectiveness of Adjuvant Radiotherapy for High Recurrence Risk Patients with Upper Tract Urothelial Carcinoma	Dr Ram Alva, Bangalore
40 min	10:10 am - 10:50 am	Moderator	Dr. Rajiv Yadav, Gurgaon
		Panelist	Dr. J Kulkarni, Mumbai
		Panelist	Dr. Sudhir Rawal, Delhi
		Panelist	Dr. B Kashyapi, Pune
		Panelist	Dr Kumar Prabhash, Mumbai
		Panelist	Dr. Gautam Choudhary, Jodhpur
		Panelist	Dr Sandeep De, Mumbai
		Panelist	Dr Rohit Malde, Mumbai
05 min	10:50 am - 10:55 am		Dr Sudhir Rawal
		SESSION 2	
		Urothelial Metastatic	
		Chairperson- MO, MO, Dr Sudhir Rawal	Dr SH Adwani, Dr Boman, Dr Rawal
10 min	10:55 am-11:05 am	LBA74 - Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC)	Dr. Adwaita Gore, Mumbai
10 min	11:05 am- 11:15 am	Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)1	Dr Amol Dongre, Nagpur
10 min	11:15 am - 11:25 am	TROPHY-U-01 Cohort 3: Sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) who progressed after platinum (PLT)-based regimens.	Dr. Bhavesh Poladia, Nammakal
10 min	11:25 am -11:35 am	ESMO 2022 EV-103 Cohort K: Enfortumab Vedotin ± Pembrolizumab in Untreated Cisplatin-Ineligible Patients With Locally Advanced/Metastatic Urothelial Carcinoma	Dr Chetna Bakshi, Mumbai
10 min	11:35 am -11:45 am	FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression	Dr. Ashay Karpe, Mumbai
30 min	11:45 am- 12:15 pm	Moderator	Dr. Chirag Desai, Ahemdabad
		Panelist	Dr Boman Dhabur, Mumbai
		Panelist	Dr Hollis Dsouza, Mumbai
		Panelist	Dr Nandni Menon, Mumbai
		Panelist	Dr Pritam Kataria, Mumbai
		Panelist	Dr Minit Shah, Mumbai

Dr. Arun Seshachala,

Dr. Abhishek Anand

